Related Experiment Video
Updated: Dec 14, 2025
Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
Published on: May 13, 2016
STAT3: A key regulator in liver fibrosis
Jie Zhao1, Yong-Fen Qi2, Yan-Rong Yu1
1Department of Pathogen Biology, School of Basic Medical Sciences, Peking University, Beijing, China.
Abstract:
Janus protein tyrosine kinase (JAK) has the ability to activate signal transducer and activator of transcription (STAT). STAT3 is a valued member of the JAK/STAT signaling pathway. In recent years, several studies have documented that STAT3 is closely related to the occurrence and development of liver fibrosis caused by various factors. Activation of STAT3 can play anti- or pro-inflammatory roles in the pathogenesis of liver fibrosis. This article reviewed the recent studies on STAT3 in the development of various liver fibrosis to find a more effective method to relieve and cure liver diseases, such as hepatitis B virus (HBV), non-alcoholic fatty liver disease (NAFLD), schistosomiasis, and chemical liver injury.
Insights
Signal transducer and activator of transcription 3 (STAT3) plays a key role in liver fibrosis development. Understanding STAT3's dual role in inflammation offers potential therapeutic targets for liver diseases.
Area of Science:
- Hepatology
- Molecular Biology
- Immunology
Background:
- The Janus protein tyrosine kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is crucial in cellular signaling.
- STAT3 is a key mediator in the JAK/STAT pathway, implicated in various biological processes.
- Emerging evidence links STAT3 to the pathogenesis of liver fibrosis from diverse etiologies.
Purpose of the Study:
- To review recent research on the role of STAT3 in liver fibrosis.
- To explore the dual anti-inflammatory and pro-inflammatory functions of STAT3 in liver disease.
- To identify potential therapeutic strategies for liver fibrosis by targeting STAT3.
Main Methods:
- Literature review of studies on STAT3 and liver fibrosis.
- Analysis of STAT3's involvement in different liver disease models.
- Synthesis of findings regarding STAT3's impact on liver inflammation and fibrosis progression.
Main Results:
- STAT3 activation exhibits context-dependent effects, acting as both an anti-fibrotic and pro-fibrotic factor.
- STAT3's role varies across different liver fibrosis etiologies, including viral hepatitis, NAFLD, schistosomiasis, and chemical injury.
- Modulating STAT3 signaling presents a potential therapeutic avenue for managing liver fibrosis.
Conclusions:
- STAT3 is a critical regulator in the development of liver fibrosis.
- Targeting STAT3 offers promising therapeutic potential for various liver diseases.
- Further research into STAT3's specific mechanisms in different fibrotic conditions is warranted.
